Related Experiment Video
Updated: Feb 6, 2026

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
Published on: February 3, 2012
Subclinical metabolic and cardiovascular abnormalities in autosomal dominant polycystic kidney disease
Insights
Autosomal dominant polycystic kidney disease (ADPKD) increases cardiovascular risk through metabolic issues and oxidative stress, even before kidney function declines. Research is needed to see if addressing these metabolic problems can improve patient outcomes.
Area of Science:
- Nephrology
- Cardiology
- Genetics
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder.
- ADPKD patients face significant morbidity from chronic kidney disease and increased cardiovascular mortality.
- Metabolic abnormalities (insulin resistance, hyperlipidemia) and subclinical cardiovascular issues (left ventricular hypertrophy) are prevalent in ADPKD.
Purpose of the Study:
- To highlight the early metabolic and cardiovascular risks associated with ADPKD.
- To underscore the role of renal oxidative stress in ADPKD progression.
- To explore potential therapeutic avenues targeting metabolic pathways.
Main Methods:
- Review of existing literature on ADPKD pathophysiology.
- Analysis of associations between metabolic derangements and cardiovascular complications.
- Consideration of findings from animal models regarding calorie restriction.
Main Results:
- Metabolic abnormalities and left ventricular hypertrophy contribute to cardiovascular risk in ADPKD.
- These complications can manifest prior to a decline in estimated glomerular filtration rate (eGFR).
- Early renal oxidative stress is implicated as a driver of disease progression.
Conclusions:
- ADPKD is linked to significant renal and cardiovascular morbidity, driven by early metabolic and oxidative stress.
- Further investigation is warranted to determine if interventions targeting metabolic abnormalities can improve ADPKD patient outcomes.
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disease. It carries high lifetime morbidity not only due to chronic kidney disease, but also due to a higher risk of cardiovascular death. Multiple metabolic abnormalities associated with ADPKD including insulin resistance and hyperlipidemia as well as subclinical cardiovascular abnormalities, such as left ventricular hypertrophy (LVH), contribute to this cardiovascular risk. These conditions may manifest before evidence of worsening estimated glomerular filtration rate (eGFR). Renal oxidative stress also occurs early in the disease and is a driver of ADPKD progression. Animal models have shown that calorie restriction may mitigate these inflammatory processes. Further research is required to show whether attenuation of metabolic abnormalities associated with ADPKD may improve renal and cardiovascular morbidity. .
More Related Videos
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
10:51A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
Published on: December 2, 2014
Related Concept Videos
Cardiovascular System Abnormal Findings I: Inspection and Palpation
Abnormal findings observed during an inspection
Cardiovascular System Abnormal Findings II: Auscultation
Abnormal Heart Sounds
Gallops:
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Incomplete Dominance
Chronic Kidney Disease I: Introduction
The Ratio of X Chromosome to Autosomes
Normal male Drosophila has a ratio of one X chromosome to two sets of autosomes. In contrast, normal female...